Viking Therapeutics, Inc. vs Regeneron Pharmaceuticals, Inc.
A head-to-head of Viking Therapeutics, Inc. (VKTX) and Regeneron Pharmaceuticals, Inc. (REGN) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | VKTX | REGN |
|---|---|---|
| Market Cap | $4.31B | $70.94B |
| P/E (TTM) | — | 16.49 |
| Forward P/E | -6.46 | 12.36 |
| P/S | — | 4.49 |
| P/B | 7.23 | 3.01 |
| EV/EBITDA | — | 13.45 |
| Dividend Yield | — | 0.40% |
| Profit Margin | 0.00% | 29.65% |
| Gross Margin | — | 85.35% |
| Operating Margin | — | 25.81% |
| Revenue Growth (YoY) | — | +19.04% |
| FCF Yield | — | 5.66% |
| Debt / Equity | — | 6.32 |
| Current Ratio | 5.72 | 3.57 |
Which is better: Viking Therapeutics, Inc. or Regeneron Pharmaceuticals, Inc.?
- ✓Larger by market cap: Regeneron Pharmaceuticals, Inc.
- ✓More profitable (net margin): Regeneron Pharmaceuticals, Inc.
Across 3 available metrics, Regeneron Pharmaceuticals, Inc. leads 2–1.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Viking Therapeutics, Inc. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.